Featured Research

from universities, journals, and other organizations

Women in their 40s have lower mammographic tumor detectability, study finds

Date:
July 30, 2010
Source:
Journal of the National Cancer Institute
Summary:
The reduced effectiveness of mammographic screening in women in their 40s is primarily due to lower detectability instead of faster tumor growth rate, according to a new study.

The reduced effectiveness of mammographic screening in women in their forties is primarily due to lower detectability instead of faster tumor growth rate, according to a study published online July 27 in The Journal of the National Cancer Institute.

Mammography screening outcomes, measured in terms of tumor size, lifetime gained and mortality, have typically been poorer in women in their forties than women in their fifties, partly because tumors of younger women tend to grow more quickly, so by the time they grow to a detectable size, they would have likely already been detected by a routine examination. Younger women also tend to have denser breast tissue, which can mask tumors, reducing their detectability on mammograms.

To investigate which factor -- faster tumor growth rates, or reduced mammographic detectability -- contributes to poorer mammography screening outcomes in younger women, Sylvia K. Plevritis of the Department of Radiology at the Stanford University School of Medicine, and colleagues, used a computer simulated model to estimate the relative effect of biology and technology on mammograms of women in their forties, compared to women in their fifties and sixties.

The researchers used the Breast Cancer Screening Simulator to create hypothetical screening scenarios whereby they could estimate the median tumor size detectable on a mammogram and the mean tumor growth rate in women aged 40-49 and 50-69.

The researchers concluded from their simulation model that lowered mammographic tumor detectability accounted for 79% and faster tumor volume doubling time accounted for 21% of the poorer sensitivity in mammography screening among younger women, compared with older women.

The authors write, "The age-specific differences in mammographic tumor detection contribute more than age-specific differences in tumor growth rates to the lowered performance of mammography screening in younger women."

One limitation of the analysis, according to the authors, is that it did not take into account that low mammographic tumor detectability could be considered a breast cancer risk factor. They write: "More research is needed to not only establish a better relationship between mammographic breast density and breast cancer risk but also understand the differences in tumor characteristics in dense vs non-dense breast tissue."


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Journal of the National Cancer Institute. "Women in their 40s have lower mammographic tumor detectability, study finds." ScienceDaily. ScienceDaily, 30 July 2010. <www.sciencedaily.com/releases/2010/07/100727162858.htm>.
Journal of the National Cancer Institute. (2010, July 30). Women in their 40s have lower mammographic tumor detectability, study finds. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/07/100727162858.htm
Journal of the National Cancer Institute. "Women in their 40s have lower mammographic tumor detectability, study finds." ScienceDaily. www.sciencedaily.com/releases/2010/07/100727162858.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins